Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Program

(2018) Ugo De Giorgi et al.   BJU INTERNATIONAL

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab

(2018) Yukihiro Toi et al.   ONCOLOGIST

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

(2018) Shifaa Abdin et al.   Cancers

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

(2017) Bernard Escudier et al.   EUROPEAN UROLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

(2017) Shunsuke Teraoka et al.   Journal of Thoracic Oncology

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

(2017) Shigeaki Suzuki et al.   NEUROLOGY

Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors

(2017) Julia Judd et al.   ONCOLOGIST

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma

(2016) Alberto Farolfi et al.   Expert Opinion on Drug Metabolism & Toxicology

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer

(2016) Omar Hasan Ali et al.   OncoImmunology

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

(2015) Martina Sanlorenzo et al.   JAMA Dermatology

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

(2015) Jennifer A. Lo et al.   JAMA Oncology

Effectiveness and Tolerability of Ipilimumab

(2014) Thomas K. Eigentler et al.   JOURNAL OF IMMUNOTHERAPY

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE